Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 26,40 € (+22,34%). La mediana è 25,88 € (+19,93%).
| Acquista |
9 |
| Mantieni |
7 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Blacksheep launches in US with prescription glasses from $3.98, targets Warby Parker and Luxottica
Blacksheep, led by CEO Pierre Wizman, is entering the U.S. market offering prescription glasses starting at $3.98 and selling designer frames for $1 with low-cost lenses, claiming on-demand production and minimal margins by cutting out middlemen. Wizman accuses incumbents of massive markups and vows to disrupt Luxottica’s dominance and Warby Parker’s pricing, while Warby Parker defends its value-driven, feature-rich products. Industry peers express skepticism about the feasibility and quality of such low-priced eyewear and note manufacturing and material costs as key differentiators. » Altro su forbes.com
Warby Parker: shareholders elect directors, ratify Ernst & Young and approve compensation
At the annual meeting shareholders elected Dave Gilboa, Youngme Moon and Ronald Williams to the board (term to 2029), ratified Ernst & Young LLP as independent auditors for 2026 and approved, in a non-binding advisory vote, the compensation of the named executive officers. About 95.97% of the voting power was represented. Warby Parker also reported Q1 results with EPS of $0.03 (below expectations) and revenue of $242.45 million (slightly above expectations), and announced an "Intelligent Eyewear" collaboration with Google and Samsung. » Altro su de.investing.com
Warby Parker misses earnings forecast, revenue slightly above expectations
Warby Parker reported Q1 2026 EPS of $0.03 versus $0.15 expected, while revenue of $242.45 million topped expectations of $239.82 million by 1.1%. Retail sales grew 13.6% year‑over‑year, while e‑commerce declined after the discontinuation of the Home-Try-On program. Adjusted gross margin and profitability are under pressure; adjusted EBITDA was $29.6 million (margin 12.2%). The company reaffirmed its full-year revenue guidance of $959–976 million and plans to invest in the planned launch of AI glasses in partnership with Google and Samsung. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 206,36 Mln | 13,40% |
| Utile lordo | 119,56 Mln | 24,05% |
| Utile netto | 4,07 Mln | 373,75% |
| EBITDA | 30,8 Mln | 265,05% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 2,65 Mld € |
Numero di azioni | 122,72 Mln |
Massimo/minimo a 52 settimane | 26,74 € - 12,91 € |
| Dividendi | No |
Beta | 1,93 |
Rapporto P/E | 379,94 |
Rapporto PEG | 0,10 |
Rapporto P/B | 7,90 |
Rapporto P/S | 3,37 |
Profilo aziendale
Warby Parker Inc. stellt Brillenprodukte her. Das Unternehmen bietet Brillen, Sonnenbrillen, lichtempfindliche Linsen, Blaulichtfilter-Linsen und Kontaktlinsen sowie Zubehör wie Etuis, Linsen-Kits mit Anti-Beschlag-Spray, Etuis und Anti-Beschlag-Linsenspray. Das Unternehmen bietet über seine Einzelhandelsgeschäfte, seine Website und seine mobilen Apps auch Augenuntersuchungen und Sehtests direkt für Verbraucher an. Am 16. Mai 2022 hatte das Unternehmen 160 Einzelhandelsgeschäfte in den Vereinigten Staaten und Kanada. Das Unternehmen war früher als JAND, Inc. bekannt und änderte im Juni 2021 seinen Namen in Warby Parker Inc. um. Warby Parker Inc. wurde im Jahr 2009 gegründet und hat seinen Hauptsitz in New York, New York.
| Nome | WARBY PARKER CL.A -,0001 Aktie |
| CEO | Neil Harris Blumenthal |
| Sede centrale | New York City,
ny Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Attrezzature e forniture sanitarie |
| Quotazione in borsa | 29/09/2021 |
| Dipendenti | 4036 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | WRBY |
Scopri gli asset
Gli azionisti di WARBY PARKER CL.A -,0001 Aktie investono anche nei seguenti asset

